NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) NIH - National Institutes of Health National Cancer Institute DCTD - Division of Cancer Treatment and Diagnosis

Are tube fill volumes below 90% a rejection criterion for all coagulation tests?

Author(s): Odabasi MS, Yalcinkaya Kara ZM

Publication: Lab Med, 2023, Vol. , Page

PubMed ID: 38104249 PubMed Review Paper? No

Purpose of Paper

This paper compared prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen levels in plasma obtained from the blood of healthy volunteers and patients taking oral anticoagulants in partially filled (50%, 60%, 70%, 80% or 90%) and completely-filled tubes.  

Conclusion of Paper

When all specimens were considered, changes in PT and APTT remained within the allowable reference change value and total allowable error when the tubes were filled to ≥70%; but when filled to ≤60%, PT and APTT were prolonged, and the percent error exceeded the total allowable error of 15%. Among healthy patients, PT was prolonged in tubes filled ≤70% and APTT was prolonged in tubes filled to ≤80%. Among patients taking oral anticoagulants, an increase in APTT was observed when tubes were filled ≤60%, whereas PT was not significantly affected by fill volumes as low as 50%. Generally, fibrinogen levels were not significantly affected by fill volume and changes remained within the allowable reference change value and total allowable error (20%) for all fill volumes investigated, but for specimens from patients on an oral anticoagulant, the fibrinogen level was reduced when the fill volume was 50%. The authors conclude that a fill volume of ≥70% meets the specifications for PT and APTT and a fill volume ≥50% is sufficient for fibrinogen.

Studies

  1. Study Purpose

    This study compared PT, APTT, and fibrinogen levels in plasma obtained from the blood of healthy volunteers and patients taking oral anticoagulants in partially filled (50%, 60%, 70%, 80% or 90%) and completely filled tubes.  Venous blood was collected using syringes from ten healthy volunteers and ten patients receiving oral vitamin K antagonist anticoagulant therapy.  Blood was immediately transferred into Sarstedt 0.2% buffered sodium citrate tubes. Tubes were filled to the fill line (2.7 mL blood, 100%), and to a volume of 90% (2.4 mL blood), 80% (2.1 mL blood), 70% (1.8 mL blood), 60% (1.5 mL blood), and 50 % (1.2 mL). All tubes were mixed by inversion. Blood was centrifuged at 2000 x g for 10 min at room temperature immediately before analysis. The normalized PT and APTT as well as fibrinogen levels were measured using a Stago Compact Max 3 coagulation analyzer. The reference change value was calculated based on the analytical and previously reported biological variation. The total allowable error was 15% for PT and APTT and 20% for fibrinogen.

    Summary of Findings:

    When all specimens were considered, changes in the PT and APTT were within allowable the reference change value and total allowable error when the tubes were filled to ≥70%; but when filled to tube volume that was ≤60%, PT and APTT were prolonged, and the percent error exceeded the total allowable error of 15%. Among healthy patients, PT was longer in tubes that were filled ≤70% (P≤0.014), and APTT was prolonged in tubes that were filled to ≤80% (P≤ 0.019). Among specimens collected from patients taking an oral anticoagulant, n increase APTT was observed when tubes were filled ≤60% (P=0.019), whereas PT was not significantly affected by fill volumes as low as 50%. Generally, fibrinogen levels were not significantly affected by tube fill volume and for all specimens remained within the acceptable reference change value and total allowable error (20%) for all fill volumes investigated, but for specimens from patients on an oral anticoagulant, the fibrinogen level was reduced when the fill volume was 50% (P=0.02). The authors conclude that a tube fill volume of ≥70% meets the specifications for PT and APTT and a fill volume of ≥50% is sufficient for fibrinogen.

    Biospecimens
    Preservative Types
    • None (Fresh)
    Diagnoses:
    • Not specified
    • Normal
    Platform:
    AnalyteTechnology Platform
    Glycoprotein Hematology/ auto analyzer
    Morphology Hematology/ auto analyzer
    Pre-analytical Factors:
    ClassificationPre-analytical FactorValue(s)
    Preaquisition Other drugs Oral anticoagulants
    None
    Biospecimen Aliquots and Components Aliquot size/volume 50% full
    60% full
    70% full
    80% full
    90% full
    100% full
    Biospecimen Acquisition Method of fluid acquisition Properly filled tube
    Improperly filled tube

You Recently Viewed  

News and Announcements

  • Just Published!

  • April 24, 2024: Biobanking for Precision Medicine Seminar

  • Most Popular SOPs in March 2024

  • More...